BEAM · Beam Therapeutics Inc
United States · RS rating 54 · As of 2026-11-03
| Price | 26.33 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 65 / 61 / 56 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 44 / 14 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +311.8% |
| Sales growth Q/Q | +1076.6% |
| Distance from 52-week high | +30.6% |
| Market cap (USD) | $3.1B |